BBIO Stock Forecast & Price Target

BridgeBio Pharma's positive outlook is supported by the projected increase in full-year 2026 revenue, rising to $766.3 million, which reflects a growing market for its key product, Attruby. The company's late-stage pipeline, particularly the promising clinical results for BBP-418 and encaleret, indicates significant potential for revenue generation and accelerated regulatory approval in the coming years. Additionally, the robust launch of Attruby, evidenced by over 5,000 unique patient prescriptions and strong month-over-month growth in the treatment-naive segment, suggests solid market demand and sales momentum.

BridgeBio Pharma faces a negative outlook due to several financial challenges, including a projected full-year 2025 net loss of $3.59 per share and a substantial quarterly net loss of $182.7 million, which exceeded both consensus estimates and previous predictions. The company is also grappling with limited cash reserves and significant debt, raising concerns about its ability to sustain operations in the face of potential clinical or commercial setbacks. Additionally, the risks associated with its drug programs, such as the potential failure of key assets like Infigratinib and competition from generics, further exacerbate the uncertainty surrounding its future financial performance.